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Abstract
Introduction Ibuprofen is a nonsteroidal anti-inflammatory drug
available over the counter and on prescription for the
management of pain and inflammation. Severe toxicity is rare
following deliberate self-poisoning with ibuprofen, and patients
are usually either asymptomatic or develop only mild
gastrointestinal toxicity. Although there have been nine other
reported fatalities, co-existent factors have probably contributed
to all of these deaths. We report here a fatality from isolated
toxicity following self-poisoning with sustained-release
ibuprofen.
Case report A 26-year-old female presented after deliberate
ingestion of up to 105 g sustained-release ibuprofen, with a
reduced level of consciousness, severe metabolic acidosis and
haemodynamic compromise. Despite intensive supportive
management, gut decontamination with multidose activated
charcoal and correction of the metabolic acidosis with sodium
bicarbonate and haemofiltration, the patient did not survive. The
ibuprofen concentration ante mortem on presentation in
peripheral blood was 760 mg/l and the concentrations post
mortem were 518 mg/l in peripheral blood, 74 mg/kg in liver
extract and 116 mg/l in the gastric contents.
Discussion Most patients with ibuprofen poisoning are either
asymptomatic or have mild gastrointestinal symptoms; severe
poisoning with ibuprofen is rare. We report the first death
related to isolated sustained-release ibuprofen poisoning.
Introduction
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID)
commonly used as an analgesic, as an anti-inflammatory agent
and as an anti-pyretic agent [1,2]. The predominant pharmaco-
logical action of ibuprofen is to inhibit the activity of cyclooxy-
genase, an enzyme crucial for the synthesis of prostaglandins.
The subsequent inhibition of prostaglandin production leads
to a reduction in inflammation, temperature and pain, both cen-
trally and peripherally. Ibuprofen is manufactured and mar-
keted as a 'normal' release preparation at a dose of 400 mg
three times a day or a sustained-release preparation at a dose
of 800–1600 mg once a day. In the United Kingdom the 'nor-
mal'-release preparation is available on general sales licence,
pharmacy and prescription, but the sustained-release prepara-
tion is available only as a 'prescription only medication'.
There have been only nine previously reported fatalities follow-
ing ibuprofen intoxication, although in eight of these cases
other co-existent factors have probably contributed to death
[3-11]. We report here the first case report of a fatality follow-
ing isolated ingestion of sustained-release ibuprofen that did
not respond to maximal supportive care with ante mortem and
post mortem ibuprofen concentrations.
Case report
A 26-year-old woman with no significant past medical history
presented after ingestion of up to 132 tablets of 800 mg sus-
tained-release ibuprofen, equivalent to approximately 105 g.
This estimate of the amount ingested was based on empty ibu-
profen packets found near her. The patient was bought into
the Emergency Department having been found collapsed and
unconscious at home by her family, who had last seen her well
approximately five hours previously. There was no history of
vomiting, gastrointestinal haemorrhage or seizures prior to
presentation at hospital. Her initial Glasgow Coma Scale was
3/15 and the patient was therefore intubated and ventilated to
provide a protected airway. On presentation she was haemo-
dynamically compromised with a systolic blood pressure of 80
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mmHg. The patient's initial electrocardiogram showed sinus
rhythm, normal QRS duration and normal QT duration, but
widespread myocardial ischaemia was noted. Initial biochem-
istry blood test results were sodium 132 mmol/l, potassium
4.7 mmol/l, urea 4.8 mmol/l, creatinine 159 µmol/l and venous
blood glucose 4.7 mmol/l. Paracetamol and salicylate concen-
trations were not detected on her admission blood samples.
Arterial blood gases showed a severe metabolic acidosis with
pH 6.99, base excess of -21 and lactate of 17 mmol/l. The
patient was commenced on epinephrine and norepinephrine
for inotropic support in view of the significant hypotension, and
the Guy's and St Thomas' Poisons Unit was contacted for fur-
ther advice on management.
Since this was potentially a life-threatening ingestion of a sus-
tained-release preparation of ibuprofen, it was recommended
that multidose activated charcoal (50 g activated charcoal
every 3–4 hours) should be given via a nasogastric tube to try
and reduce further absorption of ibuprofen from the gastroin-
testinal tract. The patient's severe metabolic acidosis should
be corrected with repeated doses of intravenous boluses of
8.4% sodium bicarbonate, and haemofiltration with a bicarbo-
nate buffer if the metabolic acidosis did not respond to intra-
venous sodium bicarbonate. Other potential common drug
and toxicological causes of a high anion gap lactic acidosis
are summarised in Table 1. It should be ensured that the
patient is adequately filled with intravenous fluid to sustain
blood pressure prior to the commencement of any additional
inotropic support.
Despite fluid resuscitation and maximal infusion doses of
epinephrine and norepinephrine, the patient remained hypo-
tensive with a systolic blood pressure of 80 mmHg. Addition-
ally her metabolic acidosis remained resistant to intravenous
sodium bicarbonate and haemofiltration with a bicarbonate
buffer, with only minor improvement to pH 7.00. Her clinical
condition continued to deteriorate and approximately five
hours post-presentation to the Emergency Department the
patient suffered a ventricular tachycardia/ventricular fibrillation
cardiac arrest, which did not respond to standard Advanced
Life Support protocol cardiopulmonary resuscitation.
Results
Serum toxicology screening
Samples of ante mortem serum were obtained following
admission and were analysed for ibuprofen by the Medical
Toxicology Laboratory in London. Post mortem samples of
peripheral whole blood, urine, gastric contents and liver extract
were analysed at the local toxicology laboratory for ibuprofen
and other drugs. Ibuprofen concentrations were measured by
high-pressure liquid chromatography with ultraviolet detection.
Ante mortem serum ibuprofen concentrations were 760 mg/l
on presentation, rising to a peak concentration of 1,050 mg/l
90 minutes after presentation. Post mortem ibuprofen concen-
trations were 518 mg/l, 264 mg/l, 116 mg/l and 74 mg/kg in
the peripheral whole blood, urine, gastric contents and liver
extract, respectively. No other drugs were detected in a broad
toxicology screen; analysis of the ante mortem and post mor-
tem serum samples only detected atracurium and lignocaine
given following admission to the hospital.
Post mortem
The cause of death was probably directly related to the ibupro-
fen overdose, since there was no evidence of another cause
of death at the post mortem examination. Of particular note
there was no evidence of cerebral oedema, no underlying
artherosclerotic disease of the coronary arteries and no evi-
dence of previous myocardial infarction. Although there was
altered blood in the gastric fluid, there was no evidence of
oesophageal or gastric erosions.
Discussion
Severe poisoning and death following poisoning with ibupro-
fen is extremely uncommon. Most cases are either asympto-
matic or experience mild gastrointestinal symptoms only [4,5].
In the case presented here the patient presented after inges-
tion of up to 105 g sustained-release ibuprofen with a reduced
Glasgow Coma Scale, a severe metabolic acidosis and signif-
icant haemodynamic compromise. Despite meticulous sup-
portive care initially in the Emergency Department and
subsequently in the intensive care unit, attempted correction
of her metabolic acidosis and the use of multidose activated
charcoal to reduce further ibuprofen absorption from the gas-
trointestinal tract, the patient did not survive. This is the first
reported case of fatality following ingestion of sustained-
release ibuprofen and the first fatality following isolated ibupro-
fen toxicity.
Ibuprofen is a NSAID commonly used as an analgesic, as an
anti-pyretic agent and as an anti-inflammatory agent [1,2]. The
predominant pharmacological effect of ibuprofen, similar to
other NSAIDs, is to inhibit the activity of cyclooxygenase (both
COX-1 and COX-2), leading to an inhibition of prostaglandin
synthesis. Following a therapeutic dose of 400 mg, the serum
Table 1
Common toxicological causes of a high anion gap lactate 
acidosis (adapted from 22)
Biguanides (for example, metformin)
Cyanide
Iron
Salicylates
Theophylline
Type B lactic acidosis (for example, from hypotension related to any 
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ibuprofen concentration is approximately 28 mg/l (range 17–
36 mg/l) [12]. Clinical features of toxicity of ibuprofen and
other NSAIDs are predictable and occur due to an inhibition of
cyclooxygenase activity.
The American Academy of Clinical Toxicology and European
Association of Poisons Centres and Clinical Toxicologists
have published a position statement on the use of multidose
activated charcoal [13]. This position statement, however con-
centrated on the evidence base for the increased elimination
of drugs undergoing enterohepatic/enteric circulation, rather
than reducing the absorption of sustained-release or modified-
release preparations.
In the case reported here a sustained-release preparation of
ibuprofen was ingested, and therefore multidose activated
charcoal was recommended to try and reduce further absorp-
tion of ibuprofen. The post mortem gastric content ibuprofen
concentration was 116 mg/l, suggesting a significant amount
of ibuprofen had still not been absorbed more than five hours
post-presentation to the Emergency Department. Another
patient who was found dead who had recently been pre-
scribed an 800 mg preparation of ibuprofen, presumed to be
a sustained-release preparation, had a post mortem total ibu-
profen concentration of 131 mg in the gastric contents [8].
Both our case and the other presumed sustained-release case
would support the use of multidose activated charcoal in the
management of patients who have ingested a sustained-
release preparation of ibuprofen in any subsequent cases.
The toxicity of ibuprofen following self-poisoning has been
reported in five large case series [3-5,10,14]. Between 80%
and 90% of the patients in these case series were either
asymptomatic or had mild gastrointestinal symptoms, such as
nausea, vomiting and diarrhoea, following ibuprofen intoxica-
tion [3-5]. Several case series have demonstrated that, in
patients with a history of ingestion of less than approximately
100 mg/kg ibuprofen, symptoms did not occur [4,5,15] and
that symptoms of ibuprofen toxicity following ingestion of a
standard release preparation usually occur within four hours of
ingestion [4,5].
Severe toxicity is uncommon following ibuprofen self-poison-
ing, and in general less than 10% of patients develop 'life-
threatening' symptoms such as coma, seizures, respiratory
arrest, hypotension or anuric renal failure [3-5,10]. Life-threat-
ening features of ibuprofen toxicity have been shown only to
occur in patients who have ingested greater than 400 mg/kg
ibuprofen [15]. Histories in patients presenting with an over-
dose have been shown to be unreliable [16], however, so to
try and predict those patients who are at risk of severe ibupro-
fen-induced toxicity, a nomogram based on the time since
ingestion and the serum ibuprofen concentration, similar to
that used for paracetamol (acetaminophen), has been devel-
oped [4]. Subsequent studies have shown conflicting results
as to whether this nomogram is accurate [5] or inaccurate [10]
at predicting those at risk of severe toxicity. Since ibuprofen
concentrations are not routinely available in most emergency
departments or hospitals, there are concerns about the accu-
racy of the nomogram, the toxic effects of ibuprofen are pre-
dictable and (unlike paracetamol poisoning) there is no
effective antidote, we would not recommend use of the ibupro-
fen nomogram in routine clinical practice.
Management of patients presenting following deliberate self-
poisoning with ibuprofen consists of gut decontamination with
activated charcoal, if they present within one hour of a poten-
tially toxic overdose, and generalised supportive care [17,18].
As already discussed, multidose activated charcoal may be
appropriate in patients who have ingested a potentially toxic
amount of a sustained-release preparation. Other more severe
features of ibuprofen toxicity should be managed appropri-
ately. Ibuprofen-induced seizures that are nonself-limiting
should initially be managed with intravenous diazepam (0.1–
0.2 mg/kg). Significant metabolic acidosis (pH < 7.0) that
does not respond to adequate intravenous fluid resuscitation,
and maintenance of the blood pressure, with intropic support
if appropriate, should be corrected with intravenous 50–100
ml boluses of 8.4% sodium bicarbonate. For resistant meta-
bolic acidosis that is not responding, then haemofiltration with
a nonlactate bicarbonate buffer may be beneficial. Although
ibuprofen has a relatively low volume of distribution (0.1 l/kg),
its high protein binding to albumin (99%) limits removal by
extracorporeal treatments such as haemodialysis or haemofil-
tration [19].
Previous studies have demonstrated no accumulation of ibu-
profen in patients with renal impairment [20] and, in function-
ally anephric patients undergoing renal replacement therapy
with haemodialysis, no accumulation of ibuprofen was seen
and there was no detectable ibuprofen in the dialysate, indicat-
ing that the ibuprofen was eliminated through metabolism
[21]. This provides further support that extracorporeal treat-
ments will probably not be beneficial in increasing the clear-
ance of ibuprofen in overdose, and there have been no
previous reported cases of their attempted use in patients with
ibuprofen toxicity. There have been no published studies on
the routine prophylactic use of H2 histamine receptor antago-
nists or proton pump inhibitors in trying to reduce the risk of
ibuprofen or other NSAID-related gastrointestinal toxicity. Our
current practice in patients with significant epigastric pain/ten-
derness after ibuprofen poisoning is to treat them with 1 week
of a proton pump inhibitor such as lansoprazole 30 mg once
daily.
There have been nine reported cases of fatality following ibu-
profen self-poisoning in the literature to date, although other
factors probably contributed to death in eight of these cases
[3-11]. The co-ingestion of other drugs at the time of the over-
dose, such as aspirin, paracetamol, theophylline andCritical Care    Vol 10 No 2    Wood et al.
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cyclobenzaprine, contributed to death in four cases [3,6,7,9].
Aspiration pneumonia that developed as a complication of ibu-
profen-induced apnoeic episodes [4] and septic shock,
thought to be unrelated to ibuprofen toxicity [10], contributed
to two deaths. Refusal of treatment of ibuprofen-induced olig-
uric renal failure and sepsis, felt by the authors to be surviva-
ble, significantly contributed to one death [5]. The
circumstances surrounding one death are unclear as the
patient was found dead near their home [8]. There are limited
details of and no confirmatory ibuprofen concentrations for the
final death, which has been reported in abstract form only [11].
Ibuprofen concentrations have been measured in four of the
previous fatalities [6,8-10]. One of the previously reported
fatalities had an ante mortem ibuprofen concentration of 72
mg/l; although few details of the case were given, the authors
concluded that the cause of death was septic shock and res-
piratory failure unrelated to the ibuprofen intoxication [10].
Peripheral blood post mortem ibuprofen concentrations of 81
mg/l, 130 mg/l and 348 mg/l have been reported in a 48-year-
old male [6], a 19-year-old male [9] and a 26-year-old male [8],
respectively.
Additionally,  post mortem ibuprofen concentrations of 942
mg/kg [8] and 238 mg/kg [6] were reported in liver extract in
two cases. In the case reported here, the post mortem ibupro-
fen concentrations were 518 mg/l in peripheral blood and 74
mg/kg in liver extract. The main differences between our
reported case and the other two cases with previous reported
post mortem ibuprofen concentrations is that our case had
higher peripheral blood and lower liver extract concentrations.
Since the exact timing of ingestion was not known in our case
and was not reported in the other two cases, the differences
in peripheral blood and liver extract ibuprofen concentrations
may be due to differences in distribution and metabolism. It is
therefore probable, given the post mortem ibuprofen concen-
trations in our reported case, that our patient died sooner after
ingestion than the other two reported cases, as peripheral
blood concentrations had not had sufficient time to fall and the
liver had not started to metabolise as much ibuprofen. The
other unknown factor in all of these cases is the impact of
impaired haemodynamics, renal dysfunction and metabolic
acidosis on ibuprofen kinetics.
Conclusion
We have described the case of a fatality following severe poi-
soning with sustained-release ibuprofen. The patient pre-
sented with a reduced Glasgow Coma Scale, severe
metabolic acidosis and haemodynamic compromise that did
not respond to meticulous supportive care, to treatment with
sodium bicarbonate, to haemofiltration and to inotropic sup-
port. There were no other toxicological or medical causes for
the patient's clinical presentation. Multidose activated char-
coal was utilised in this patient due to the ingestion of a sus-
tained-release preparation, and its use was supported by
elevated ibuprofen concentrations in the gastric contents fol-
lowing death.
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